326827-23-0

Basic information

• Product Name: 3-Cyclopropyl-5-nitro-1H-pyrazole
• Synonyms: 3-Cyclopropyl-5-nitro-1H-pyrazole;3-cyclopropyl-5-nitro-2H-pyrazole
• CAS NO: 326827-23-0
• Molecular Formula: C6H7N3O2
• Molecular Weight: 153.13868
• Mol File: 326827-23-0.mol

Chemical Properties

• Boiling Point: 351.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.519±0.06 g/cm3(Predicted)
• PKA: 8.88±0.10(Predicted)
• CAS DataBase Reference: 3-Cyclopropyl-5-nitro-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Cyclopropyl-5-nitro-1H-pyrazole(326827-23-0)
• EPA Substance Registry System: 3-Cyclopropyl-5-nitro-1H-pyrazole(326827-23-0)

Safety Data

• Hazardous Substances Data: 326827-23-0(Hazardous Substances Data)

Upstream product

• 175137-46-9 5-cyclopropyl-2H-pyrazol-3-ylamine 
• 144-55-8 sodium hydrogencarbonate 
• 175137-46-9 3-amino-5-cyclopropyl-1H-pyrazole 

Relevant articles and documents

3-Acylaminopyrazole derivatives via a regioselectively N-protected 3-nitropyrazole

A simple procedure for the selective protection of the endocyclic 1-N of 3-aminopyrazoles as tert-butoxycarbamate (Boc) in good yield is described. A 3-nitropyrazole derivative represents the key intermediate with the nitro substituent determining the regiochemistry of the obtained protected compound. Subsequent acylation at the exocyclic amino group gave rise, after Boc removal, to a series of 3-acylaminopyrazoles in high yields and purities.

3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents

3-ureido-pyrazole derivatives represented by formula (I): where R, R1and R2are as described herein, or pharmnaceutically acceptable salts thereof; are useful, for example, for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.

3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents

Compounds which are 3-amino-pyrazole derivatives represented by formula (I): where R is a C3-C6cycloalkyl group, which may optionally be substituted by a straight or branched C1-C6alkyl group, and R1is a straight or branched C1-C6alkyl group or a C2-C4alkenyl, cycloalkyl, aryl, arylalkyl, arylcarbonyl, aryloxyalkyl and arylalkenyl, which may be optionally substituted; or a pharmaceutically acceptable salt thereof. The compounds are useful for the treatment of cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases or neurodegenerative diseases.